Liquid biopsy is the molecular examination of nucleic acids, subcellular structures, particularly exosomes, and, in the case of cancer, circulating tumour cells in bodily fluids. Liquid biopsy has been the subject of intense research over the last ten years in order to develop a less intrusive and more precise individualised therapy. Tissue biopsy can be supplemented or even replaced by a molecular analysis of these circulating biomarkers. Liquid biopsy has been used in clinical practise as a result of this research, particularly in oncology, prenatal screening, and transplantation. Liquid biopsy is a ground-breaking procedure that is providing previously unimaginable insights. With advances in technology and lower costs, liquid biopsy may be able to supplement medical imaging for cancer detection and staging. For cancer patients undergoing local-regional therapy, radiologists may be able to use liquid biopsy techniques to help with treatment selection and post-procedural management.
Title : Copper (II) complexes as potential anticancer agents
Salah S Massoud, University of Louisiana, United States
Title : Pharmacogenomics: current status and future directions
Matthias Schwab, University of Tübingen, Germany
Title : Talus bone of the hindfoot: Unique anatomy and an important clinical implication
Abdelmonem Awad Hegazy, Zarqa University, Jordan
Title : The use of anti seizure medication therapeutic blood level determination to personalise the treatment of epileptic seizures especially in patients attending the accident and emergency department
Roy Gary Beran, University of New South Wales, Australia
Title : Effect of Fluvoxamine on Interluekin-6 level of COVID-19 patients, hospitalized in ICU: A randomized clinical trial
Mitra Safa, Shahid Beheshti University of Medical Sciences, Iran (Islamic Republic of)
Title : Precision Treatment of Alzheimer's
Boris Tankhilevich, Magtera, Inc., United States